Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc. is a U.S.-based pharmaceutical company centered on Endari®, an oral L-glutamine therapy used in sickle cell disease. The company commercializes the product through distributors and pharmacy channels in the U.S. and also sells into the MENA region, while relying on external financing to support operations.

2,2 %

93,1 %

−60,2 %

−25,2 %

0.11

0.09

— Emmaus Life Sciences, Inc.
%
Endari® product sales95% Commercial sales of Endari®, the company's core prescription therapy for sickle cell disease.
U.S. distribution channel sales3% Sales routed through nonexclusive distributors, PBMs, and pharmacy networks in the United States.
MENA region sales2% Product sales in the Middle East and North Africa, which add geographic diversification but remain smaller than U.S. sales.

Emmaus sells primarily to patients with sickle cell disease through a healthcare reimbursement chain that includes...

  • U.S. sickle cell disease patientsprimary

    Patients prescribed Endari® for sickle cell disease; they buy through pharmacies, with reimbursement support critical to access.

  • U.S. distributors and pharmacy channelsprimary

    Nonexclusive distributors, specialty pharmacies, and PBMs that move Endari® into retail and specialty pharmacy networks.

  • Government payorsprimary

    Medicare and Medicaid programs that reimburse Endari® and materially affect affordability and volume.

  • Commercial payorssecondary

    Private insurers and managed care organizations that determine formulary access and reimbursement rates.

  • MENA market buyerssecondary

    Regional buyers and channel partners purchasing Endari® in the Middle East and North Africa.

The business is anchored in the United States, where Endari® is sold through national distribution and reimbursement...

  • •United States is the core market for Endari® sales
  • •MENA contributes additional revenue but is more timing-sensitive
  • •Nationwide U.S. pharmacy access supports broad prescription availability
  • •Reimbursement coverage in Medicare, Medicaid, and commercial plans matters
  • •API supply arrangements create operational dependence outside the U.S.

Emmaus is focused on stabilizing and rebuilding Endari® sales after generic L-glutamine entry pressured U.S...

01
Protect Endari® market share and reimbursementshort-term

Generic L-glutamine competition has reduced U.S. sales and pressured pricing.

02
Preserve liquidityshort-term

Cash balances are very low and the company needs external funding to continue operations.

03
Streamline commercialization costsshort-term

Lower fixed costs help offset revenue pressure and extend runway.

The company faces acute liquidity risk because cash is minimal and operating losses continue, making external financing...

critical

Liquidity shortfall

Cash and cash equivalents are very low and the company says it lacks sufficient operating capital without new funding.

Scope
Ability to fund operations and debt obligations
Materiality
high
high

Generic competition for L-glutamine oral powder

ANI's generic launch has adversely affected Endari® sales and reimbursement rates.

Scope
U.S. Endari® revenue and pricing
Materiality
high
high

Reimbursement and payor access

Endari® depends on Medicare, Medicaid, and commercial coverage for volume and affordability.

Scope
Prescription demand and net revenue realization
Materiality
high
medium

Debt and financing structure

Convertible notes, other notes payable, and related-party financing can increase interest expense and dilution risk.

Scope
Capital structure and earnings
Materiality
medium
medium

MENA revenue timing

Management noted that regional sales timing can move quarterly results materially.

Scope
Quarterly revenue volatility
Materiality
medium
Revenue recognition on product sales
Net revenue timing and gross-to-net deductions
Fair value of conversion feature derivative
Earnings volatility
Convertible notes and other notes payable
Net loss and capital structure
Stock options and warrants
Operating expense and diluted share count
Lease accounting
Reported operating costs and balance sheet obligations

GERON CORP

GERN · Pharmaceutical Preparations

AMICUS THERAPEUTICS, INC.

Pharmaceutical Preparations

ENDRA Life Sciences Inc.

NDRA · Electromedical & Electrotherapeutic Apparatus

Entera Bio Ltd.

ENTX · Biological Products, (No Diagnostic Substances)

Journey Medical Corp

DERM · Pharmaceutical Preparations

Tempus AI, Inc.

TEM · Services-Computer Programming, Data Processing, Etc.

: 28/04/2026